Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 64 years old (of any gender) at the start of the study.
- People who have a confirmed diagnosis of ulcerative colitis and whose doctor has independently decided to prescribe them etrasimod for moderately to severely active ulcerative colitis, in line with the medication's approved use.
- People who have read, understood, and signed a consent form agreeing to take part in the study.
Who may not be able to join:
- People whose symptoms suggest they may have Crohn's disease rather than ulcerative colitis.
- People whose doctor believes they are likely to need hospitalisation for a medical or surgical procedure related to their ulcerative colitis (such as removal of the colon) within the next 12 weeks.
- People currently showing signs of acute severe ulcerative colitis, a sudden serious flare (fulminant colitis), or a life-threatening complication called toxic megacolon.
- People who already have a stoma (a surgical opening in the abdomen) or who have a planned ulcerative colitis surgery that would require hospitalisation.
- People who have previously taken etrasimod at any time, including in a previous clinical trial involving this medication.
- People currently taking certain other medications alongside etrasimod, including methotrexate, azathioprine, mercaptopurine, or tioguanine; or advanced treatments such as biologic therapies (TNF, integrin, or cytokine blockers), JAK inhibitors (filgotinib, tofacitinib, or upadacitinib), or any other medication in the same class as etrasimod (S1P receptor modulators).
- People who do not own a digital device with internet access, are unwilling to complete health questionnaires on such a device, or are unable to use the questionnaire tool provided.
- People who work at the trial site or are employed by Pfizer and are directly involved in running the study, as well as their immediate family members.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients with symptomatic remission; Proportion of patients with symptomatic remission
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.